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Abstract: The most studied phyto constituent isolated from Virola surinamensis 
(Rol. ex Rottb.) Warb., Myristicaceae, is the tetrahydrofuran neolignan grandisin, 
which exhibits a series of biological activities, including trypanocidal, larvicidal and 
antitumoral. Due to its extremely low solubility, additional studies, including in vivo 
investigations are challenged by the diffi culties in the development of an effective 
drug delivery system for grandisin. The encapsulation in polymeric nanoparticles is 
a very attractive alternative for overcoming some of these limitations. In this work, 
PLGA nanocapsules loaded with grandisin were developed in an attempt to optimize 
the effi cacy of grandisin as an antitumoral drug, with high drug loading and effi ciency, 
prolonged drug release and increased physical-chemical stability. Mean diameter of 
the nanocapsules was lower than 200 nm, with very low polydispersity. Encapsulation 
effi ciency was above 90%. A sustained in vitro drug release was achieved for up to 
twenty days and cytotoxicity was markedly increased (IC50 for grandisin-NC and 
grandisin were 0.005 μM and 0.078 μM, respectively), indicating that polymeric 
nanocapsules are a potential drug delivery system for grandisin allowing the preparation 
of formulations viable for further in vivo studies. 
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Introduction
 Virola surinamensis (Rol. exRottb.) Warb., 
Myristicaceae, popularly known as “ucuúba-branca” or 
“ucuúba-de-igapó”, has been used in folkmedicine in the 
treatment of erysipelas, colic and dyspepsia (Schultes 
& Holmstedt, 1971). Phytochemical investigations 
on these species revealed the presence of steroids, 
flavonoids, polyketide, tetrahydrofuran lignans and 
one aryltetralinneolignan. Currently, the most studied 
phytoconstituent isolated from Virola surinamensis 
is the tetrahydrofuran neolignan grandisin (GRAN). 
The tetrahydrofuran lignans isolated from adult leaves 
and woods showed high trypanocidal activity against 
the tripomastigote forms of Trypanosoma cruzi, the 
aetiologic agent of Chagas disease (Lopes et al., 1996; 
Lopes et al., 1998). Additionally, in vitro effectiveness 
of GRAN as larvicidal agent against Aedesaegypti 
and Chrysomyamegacephala has been demonstrated 
(Nogueira et al., 2009; Cabral et al., 2009).
 More recently, in vivo studies have demonstrated 
that GRAN has antinociceptive and anti-inflammatory 
properties (Carvalho et al., 2010). Also, our research 
group demonstrated its marked antitumoral activity 
against Ehrlich ascites tumor experimental model 
(Valadares et al., 2009) and an important antileukemia 
activity on K-562 cell line(Valadares et al., 2011). 
 GRAN, however, presents challenging 
properties regarding the development of dosage 
forms appropriate for further in vivo investigations. 
These undesirable properties include a practically 
null hydrosolubility and high lipophilicity, which 
has been considered a limiting factor to address 
pharmacological and toxicological investigations in 
animals. Therefore, investigations on the development 
of suitable formulations in order to improve GRAN 
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pharmacokinetics, which is associated with the efficacy 
of antitumoral drugs, are necessary. Likewise, the 
increase of an apparent drug solubility and the control of 
drug release could also improve GRAN drug delivery. 
 The encapsulation of drugs in polymeric 
nanoparticles is a very attractive alternative for 
overcoming some of these limitations. Polymeric 
nanoparticles, such as poly(lactic-co-glycolic acid) 
(PLGA) nanoparticles, have been extensively used 
for the encapsulation of lipophilic drugs (Budhian et 
al., 2007). These nanoparticles are able to increase 
drug concentration in the formulation, maximizing 
the amount of drug in tumor cells. Moreover, due to 
the EPR effect (enhanced permeability and retention 
of solid tumors), more particles may be retained in 
the tumor, releasing the cytotoxic drug in a controlled 
manner (Souza et al., 2011). 
 Thus, the aim of this work was to develop 
GRAN-loaded PLGA nanocapsules using interfacial 
deposition of the preformed polymer (nanoprecipitation), 
in an attempt to optimize the efficacy of GRAN as an 
antitumoral drug, with high drug loading and efficiency, 
prolonged drug release and increased physical-chemical 
stability. 
Materials and Methods
Materials
 Poly(lactic-co-glycolic acid) (PLGA) and 
poloxamer (Pluronic F68® and Pluronic F127®) were 
from Sigma-Aldrich (USA), soy phosphatidylcholine 
99% (PC) was from Lipoid Gmb (Germany). Ultrapure 
Milli-Q water was used throughout the study. All other 
chemicals were of analytical grade or higher.
Grandisin
 Grandisin (GRAN) (molecular weight: 432.2) 
was obtained from the leaves of Virola surinamensis 
(Rol. ex Rottb.) Warb., Myristicaceae, similarly to 
a previously reported method (Martins et al., 2000). 
The plant material was collected at Combu Island 
(01°30'10"S; 048°27'42"W), near Belém-PA, Brazil. A 
dry voucher sample (LOPES-037) has been deposited 
in the SPF-Herbário do Instituto de Biociências da 
Universidade de São Paulo.
 A fraction (1.7 g) from crude EtOAc extract 
obtained V. surinamensis leaves was submitted to a 
column chromatography under vacuum (h:d: 150 x 
100 mm) using hexane:EtOAc (4:1-4:1) yielding 22 
fractions. A pooled fraction (16-20) was submitted to 
recrystalization in MeOH yielding 80mg of grandisin. 
The HPLC analysis using C-18 column [250x5 mm, 
5μm particle, detector set at 250 nm; MeOH:H2O, 
1:1(5´)-1:0(30´) 1 mL/min] indicated chromatographic 
purity >99% (Figure 1). The identity of the grandisin 
was confirmed by direct chromatographic comparison 
with authentic standard compound previously isolated 
and by 1H NMR spectrum (Martins et al., 2000).
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Figure 1. HPLC analysis of grandisin isolated from Virola 
surinamensis.
Analytical procedure
 The amount of GRAN in the nanocapsules 
was determined by a UV high-performance liquid 
chromatography method (HPLC), with Varian ProStar 
separation module equipped with a ProStar 310 UV 
detector, ProStar 240 solvent delivery pump and a 
ProStar 410 auto injector system (Varian Inc., USA). 
Separation was performed in a Lichrosphere 100 RP-18 
(250 mm ×4.6 mm, 5 μm, Darmstadt, Germany, Merck) 
column. The mobile phase was H2O:ACN:MeOH 
(20:10:70 v/v/v) at a flow rate of 1 mL/min, injection 
volume of 50 μL, 25°C. Elution time for GRAN peak 
was 2.24 min and detection was carried out at 269nm. 
A linear calibration curve (y=4.099x-3.683; r=0.9999) 
was obtained over the working concentration range of 
50-150 μg/mL.
 The amount of GRAN quantified in receptor 
solution (for the release studies) was determined 
with the following modifications to the previously 
described chromatographic method: the mobile phase 
was H2O:ACN:MeOH (20:30:50 v/v/v) at a flow rate 
of 1.8 mL/min, injection volume of 50 μL, 25°C. The 
same RP-18 column was used. Elution time for GRAN 
peak was 3.8 min and detection was also carried out 
at 269 nm. A linear calibration curve (y=6.319x-0.075; 
r=0.9999) was obtained over the working concentration 
range of 0.8-50 μg/mL.
Preparation of GRAN nanocapsules (GRAN-NC) 
 Grandisin-loaded nanocapsules dispersions 
(GRAN-NC) were prepared by interfacial deposition 
of the preformed polymer (nanoprecipitation), based 
on the method proposed by Fessi (1989). Briefly, the 
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organic phase containing PLGA (150 to 200 mg), PC 
(150 mg), soybean oil (100 mg), methanol (5 mL), 
acetone (22 mL) and different amounts of GRAN (5, 
8, 10 e 12 mg) was mixed at room temperature. The 
aqueous phase consisted of phosphate buffer pH 7.4 
with 150 mg of Pluronic F68® or a mixture of Pluronic 
F68® and Pluronic F127® (1:1). The organic phase was 
slowly injected into the aqueous phase under magnetic 
stirring, with the aid of a 10 mL syringe attached to 
a needle with 0.3175 mm internal diameter. The 
nanoemulsion remained under magnetic stirring for 30 
min at room temperature. Then, the organic solvents 
were removed by evaporation under reduced pressure 
(600 mmHg) at 40°C, in a rotary evaporator, to a final 
volume of 10 mL. Blank nanocapsules without GRAN 
(blank NC) were also obtained. 
Physicochemical characterization of nanocapsules
 Physical aspect, particle size and zeta 
potential
 Nanocapsules dispersions were observed 
for their homogeneity, color, presence of residue or 
precipitates and phase separation. The mean diameter 
(nm) and polydispersity index (PdI) of GRAN-NC 
dispersions (diluted 1:200 with purified water) were 
measured by dynamic light scattering (Zetasizer Nano 
ZS, Malvern Instruments Ltd., Worcestershire, UK) at 
25oC. Zeta potential was measured by eletrophoretical 
mobility and analyzed in folded capillary cells with the 
same instrument and experimental conditions. 
 Entrapmentefficiency (EE%) 
 In order to isolate the entrapped GRAN from 
the free drug, 1 mL of recently prepared GRAN-NC 
dispersions were centrifuged (1620 x g) for 15 min. 
Precipitate containing free drug was dissolved with 
methanol and withdrawn for HPLC analysis (see section 
2.3). All analyses were performed in triplicate. Total 
amount of drug incorporated in NC was determined by 
disrupting the nanocapsules with methanol followed 
by HPLC quantification. The entrapment efficiency 
(EE) and drug loading (DL), were determined using 
Equation 1 and 2:
                                                       (1)
                                                        (2)
Stability studies
 GRAN-NC dispersions were stored at 4±2°C 
for thirty days. Stability was evaluated by comparing 
the initial particle size, PdI (polydispersity index), pH 
and GRAN initial concentration with those obtained 
from samples withdrawn after 1, 5, 10 and 30 days of 
storage at 4°C. 
In vitro release studies 
 Drug release was evaluated by a dialysis-
diffusion method. One mililiter of GRAN-NC (with 1 
mg/mL of GRAN) was introduced into a dialysis bag 
(regenerated cellulose membrane with a molecular 
weight cut-off of 12,000-15,000 Da). The release 
experiment was initiated by placing the dialysis bag 
in 10 mL of a recipient medium (phosphate buffer pH 
7.4 with 5% sodium dodecyl sulfate (SDS), to maintain 
sink conditions) stirred at 100 rpm and 37°C. At 
predetermined intervals (3, 6, 9, 12, 24, 36, 48 h; 3, 4, 
5, 6, 7, 8, 9, 10, 11, 13, 15, 17, 19, 21 days), aliquots 
(500 μL) of the recipient solution were withdrawn and 
replaced with fresh medium. Samples were analyzed 
for GRAN content by HPLC. 
Cytotoxicity studies
 Balb/c 3T3-A31 fibroblasts were cultured in 
Dullbecco’s Modified Eagle’s Medium (DMEM-D5648 
Sigma Aldrich), supplemented with 10% fetal bovine 
serum (FBS-GIBCO), 100 IU/mL penicillin, and 100 μg/
mL streptomycin, and routinely grown as a monolayer 
in 75 cm2 tissue culture flasks (TPP) at 37±1oC, 90±10% 
humidity, 5.0±1.0% CO2/air. The cells were examined 
in a daily basis under a phase contrast microscope, and 
any changes in their morphology or adhesive properties 
were registered. For the experiment, cells were 
removed from the culture flasks using trypsinization 
(0.25% trypsin and 0.02% EDTA solution) when they 
exceeded 50% confluence but before reaching 80% 
confluence. A cell suspension containing 3x104 cells/
mL was prepared on the day of plate seeding using 
culture medium supplemented with 10% FBS. The first 
row (blanks) of 96-well microliter plates were seeded 
with 100 μL routine culture medium and the remaining 
wells received 100 μL of a suspension containing 
3x104 cells/mL (3x103 cells/well) and were incubated 
for 24±2 h (37±1oC; 90 ±10% humidity, 5.0±1.0% CO2/
air) so that the cells could form a monolayer less than 
50% confluent. This incubation period assured the cell 
recovery and adherence and progression to exponential 
growth phase. For neutral red uptake (NRU) assays, 
a Balb/c 3T3-A31 cell suspension containing 3 x 104 
cells/well was seeded in 96-well plates and after 24 
h, time required for the growing cells to attach to the 
bottom of the flask and for cell recovery, they were 
treated with eight different concentrations of freshly 
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prepared test GRAN or GRAN-NC in complete medium 
(six wells per concentration) and incubated for 48 h. 
The control wells (blanks) received complete culture 
medium supplemented with 10% FBS. After that, 250 
μL of neutral red (NR) medium were added to all wells, 
including the blanks, and incubated (37±1oC, 90±10% 
humidity, 5.0±1.0% CO2/air) for 3±0.1 h. The cells were 
briefly observed between 2 and 3 h after incubation for 
NR crystal formation. After 3 h, the NR medium was 
removed and the cells were carefully rinsed with 250 
μL/well of pre-warmed PBS. The PBS was decanted 
from the plate and 100 μL of NR desorb (50 EtOH: 
1CH3CO2H: 49 H2O) solution were added to all wells, 
including the blanks. The plates were rapidly shaken 
on a microplate shaker for 20 min to extract NR from 
the cells and to form a homogeneous solution. The 
absorption was measured 545 nm in a microtiter plate 
reader (spectrophotometer). The optical density (OD) 
was calculated as the difference between the absorbance 
at the test wavelength and the reference wavelength. 
For each concentration tested, wells containing all the 
reagents used but no cells served as reference blanks.
Statistical analysis
 Data from the microtiter plate reader were 
transferred to a spreadsheet template Microsoft Office 
Excell 2007® for the calculation of cell viability, IC50 
values by linear interpolation, and statistical analyses. 
Concentration-response curves were constructed and 
fitted in Microsoft Office Excell 2007® using parametric 
nonlinear regression. IC50 values were computed using 
the fitted Hill equation and presented as mean±SD of at 
least two independent experiments. Each experiment 
was carried out in sixrepetitions (twelve values for each 
compound).
Results and Discussion 
Nanocapsules preparation
 Previously to the encapsulation of GRAN-
NC, blank nanocapsules were prepared with different 
concentrations of PLGA and surfactants. Table 1 shows 
mean diameter and polydispersity index (PdI) values 
obtained from the different nanocapsules formulation. 
 Nanoparticles obtained with 150 mg of 
Pluronic F68® and different concentrations of PLGA 
did not presented significant differences in mean 
diameter (p>0.05). However, the increase in PLGA 
concentration also increased PdI values (p<0.05), 
probably due to aggregation of the free polymer chains 
that did not form nanocapsules. Nanoparticles obtained 
with the mixture of poloxamers and lower amount of 
PLGA (150 mg) had a smaller diameter and a narrower 
size distribution (p<0.05). Since surfactants play a 
main role in the formation of the nanodispersion, the 
combination of surfactants with different molecular 
weights (8,400 and 12,600 for Pluronic F68® and 
Pluronic F127®, respectively) favored the formation of 
smaller nanoparticles (Liu et al., 2011). Nanocapsules 
obtained with the mixture of poloxamers were then 
selected for GRAN incorporation. 
Table 1. Mean diameter and PdI values of nanocapsules 
prepared with different amount of PLGA and poloxamers.
PLGA 
(mg)
Pluronic F68®: 
Pluronic F127® (mg)
Mean diameter 
(nm)a PdI
a
200 150:0 218.0±18.4 0.547±0.002
165 150:0 206.0±12.7 0.454±0.011
150 150:0 212.0±11.3 0.379±0.009
150 75:75 188.4±3.50b 0.139±0.023b
aMean±SD of at least three measurements; bNanocapsuleswere 
smaller and less polydisperse than the other formulations (p<0.05).
Physicochemical characterization of GRAN loaded 
nanocapsules
 GRAN-NC dispersions were successfully 
obtained by interfacial deposition of the preformed 
polymer (nanoprecipitation). In an attempt to achieve 
high encapsulation efficiencies (EE) and drug loading 
(DL), different amounts of GRAN were added to the 
Table 2. Mean diameter, polydispersity index (PdI), entrapment efficiency (EE), drug loading (DL) and zeta potential of 
nanocapsules with and without GRAN*.
Amount of GRAN 
added (mg/mL)
Mean diameter 
(nm)a PdI
a EE 
(%, w/w)a
DL 
(%, w/w)a Zetapotential (mV)
a
- 163.2±1.56 0.140±0.006 - - -5.50±0.85
0.5 174.9±1.98 0.115±0.008 100.22±0.84 3.34±0.02 -6.64±0.55
0.8 170.1±1.27 0.135±0.019 100.00±0.35 5.33±0.02 -8.60±0.29
1.0 169.5±0.28 0.141±0.004 98.20±0.65 6.54±0.04 -10.82±0.43b
1.2 173.2 ±0.35 0.121±0.041 90.45±0.38 7.23±0.03 -14.06±2.32b
*Formulations obtained with 150 mg of PLGA and 150 mg of a mixture of Pluronic F68® and Pluronic F127® (1:1); aMean±SD of at least 
threemeasurements; bGRAN-NC presented higher zeta potential (in modulus) compared to the GRAN-NC with 0.5 mg/mL (p<0.05). 
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PLGA nanocapsules formulations (5, 8, 10 e 12 mg), 
resulting in concentrations of 0.5, 0.8, 1.0 and 1.2 mg/
mL of GRAN. Table 2 demonstrates physical-chemical 
characteristics of the nanocapsules.
 Higher amounts of GRAN in the formulation did 
not alter significantly the size and PdI of nanocapsules 
(p>0.05). GRAN loading in the nanocapsules ranged from 
3.3 to 7.20% (w/w). However, the addition of more than 1.0 
mg of GRAN significantly increased the amount of non-
encapsulated drug, which reduced entrapment efficiency 
values to about 90%, indicating that a maximum efficiency 
had been reached.
 Also, zeta potential data demonstrated that the 
increase of the amount of GRAN in the formulation 
increased (in modulus) zeta potential values (p<0.05), 
which was probably related to the surface-associated 
drug in the nanocapsules, as previously reported in the 
literature (Souza et al., 2011). The following studies 
were performed with the formulation containing 1 
mg/mL of GRAN, since this formulation showed the 
highest EE, a small and uniform size, and a high DL 
value (Table 2).
Stability studies
 Stability studies of GRAN-NC were performed 
in order to assess the influence of nanoparticles 
ingredients on the stability of the colloidal suspensions. 
For this purpose, mean diameter, PdI, entrapment 
efficiency (EE) and pH of GRAN-NC dispersions were 
determined after different storage times (1, 7, 15, 30, 
90 days) at 4oC for thirtydays. Stability data are shown 
in Table 3. 
 After thirtydays, GRAN-NC dispersions 
were apparently homogeneous, without any visible 
precipitates, phase separation or flocculation. Until 
tendays, GRAN-NC did not exhibit alterations in 
particle size and PdI (p<0.05). In 30 days, slightly 
increase in size and PdI could be observed without any 
loss in the homogeneity of the formulation. Entrapment 
efficiency and pH decreased with time. The decrease in 
GRAN-NC entrapment efficiency could be an indicator 
of PLGA degradation during the experiment. It has 
been discussed that polymer degradation usually leads 
to a drop in pH value (Mathias et al., 2006), which was 
observed in these formulations. Thus, it seems that a 
small amount of GRAN was released during storage due 
to polymer degradation in the aqueous environment.
In vitro release studies 
 Previous studies have demonstrated that the 
slow and prolonged release of antineoplasic drugs 
could modify drug cytotoxicity due to modifications on 
the exposure profile of the cancer cells to drugs (Souza 
et al., 2011). As GRAN has a great potential as an 
antineoplastic drug (Valadares et al., 2009), the release 
profile of GRAN from nanocapsules was determined 
and the results are shown in Figure 1. Diffusion of 
free GRAN through the cellulose membrane was faster 
than from the drug encapsulated in nanocapsules. 
Approximately 65% of GRAN is released from a 
micellar dispersion in 48 h, while only 30% of GRAN 
was released from nanocapsules. 
Figure 2. Diffusion of free GRAN and GRAN-NC through 
the cellulose membrane in 48 h of experiment.*p<0.05.
 Drug release experiments of GRAN-NC were 
also performed for 21 days to determine the drug 
release profile for a longer period of time. Figure 2 
demonstrates that 52% of GRAN is released from 
nanocapsules in 21 days. 
  Thus, in the first 48 h, approximately 31% 
of the drug was released from nanocapsules, and 
only 21% of the drug was additionally released in the 
Table 3. Mean diameter, PdI, entrapment efficiency and pH of GRAN-NC dispersions during stability evaluation at 4oC.
Time (days) Mean diameter (nm)a PdIa Entrapment efficiency (%, w/w)a pHa
0 161.5±0.35 0.123±0.01 99.99±0.24 7.24±0.001
1 159.4±0.78 0.115±0.01 100.37±0.53 7.33±0.006
5 161.1±0.42 0.150±0.02 96.30±0.28c 7.26±0.012
10 160.5±0.85 0.120±0.04 96.13±0.04c 7.25±0.006
30 257.5±1.20b 0.270±0.01b 93.55±0.50c 7.10±0.015d
aMean±SD of at least threemeasurements, bMean diameter and PdI increased in thirtydays (p<0.05); cEntrapment efficiency decreased compared to 
the initial concentration (day 0 and 1) (p<0.05); dpH decreases compared to the initial value (day 0) (p<0.05). 
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followingninetenn days. This two-stage release may be 
related to the design of the nanocapsules, since they 
present a core-shell type structure, in which the drug 
could be associated to the surface of the nanocapsules 
and/or dissolved into the core (Melo et al., 2011). As 
such, in this experiment, within the first 48 h, GRAN 
surface-associated is released and then, as GRAN is a 
highly lipophilic drug, the remaining drug dissolved 
in the oily nucleus is released from nanocapsules in 
a sustained manner. In summary, GRAN-NC seems 
to be a potential carrier for GRAN delivery, whereas 
high drug loading and sustained drug delivery was 
achieved. 
Figure 3. Release of grandisin from PLGA nanocapsules.
In vitro cytotoxicity studies
 Studies have shown that nanoencapsulation could 
increase the drug uptake into cells, which, in turn, increases 
drug cytotoxicity. Also, nanoencapsulation of cytotoxic 
drugs has been considered a great strategy to overcome 
multidrug resistance, i.e. the efflux of free drug caused 
by glycoproteins overexpressed in tumor cell membranes 
(Wong et al., 2007).
 In an attempt to verify if PLGA nanocapsules 
could increase GRAN cytotoxicity, in vitro cytotoxicity 
studies were performed with NRU assay and 3T3 cell 
lines. Different concentrations of GRAN-NC and free 
GRAN (2.31; 1.16; 0.58; 0.29; 0.14; 0.07; 0.04; 0.002 
μg/mL) were added to the cell culture, which was 
incubated for 48 h. The IC50 values for GRAN-NC and 
GRAN were 0.005 μM and 0.078 μM, respectively.
 The decrease in IC50 value for nanocapsules 
showed that the nanoencapsulation modified the 
cytotoxic profile of the GRAN on fibroblast cells, 
which might be related to the increase in drug cellular 
uptake from PLGA nanocapsules. It has been reported 
that while free drug enters the cells by passive diffusion, 
nanoparticles could be internalized by endocytosis 
(Zhao et al., 2011; Oh et al., 1999), and this mechanism 
of internalization could also occur in tumor cells (Zhao 
et al., 2011). In addition, studies reported that in vivo 
administration of nanoparticles may increase drug 
accumulation in solid tumors due to their irregular 
vasculature (EPR effect) (Souza et al., 2011). Thus, 
GRAN nanoencapsulation has potential to be a more 
effective form to treat tumors, since it can be related to 
a higher cellular uptake and drug accumulation in the 
tumor tissue. Further experiments will be performed 
in different cell lines and in vivo, in order to study 
GRAN cellular uptake and tissue accumulation of 
nanocapsules. 
Conclusion
 In this work GRAN, isolated from Virola 
surinamensis (Rol. ex Rottb.) Warb., Myristicaceae was 
successfully loaded in a PLGA nanocapsule dispersion. 
Nanoencapsulation sustained GRAN release, provided 
chemical stability and altered its cytotoxicity. GRAN-
NC seems to be a potential carrier for GRAN delivery for 
further in vivo studies.
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